AstraZeneca shares have risen 80p to 10,870p and Barclays by 1.15p to 362.35p after the blue-chip heavyweights released ...

Drugmaker Astrazeneca said on Tuesday that "strong growth momentum" had continued in H1, with "excellent R&D pipeline ...

(Alliance News) - AstraZeneca raised its dividend as drug growth pushed earnings higher, Barclays launched a new buyback programme after profit jumped while Greggs saw profit fall despite higher sales ...

Revenue from oncology products made up 43 per cent of Astrazeneca's revenue in the first half of 2025, up 15 per cent year on ...

AstraZeneca PLC (NASDAQ: AZN) ranks among the stocks to benefit from an onshoring boom. AstraZeneca PLC (NASDAQ:AZN) ...

Democrats assert in the court case that the vote of a Senate committee rejecting the appointees means they cannot serve. A ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

AstraZeneca's shares are up 3.5% over the year to date but remain down 11% over the past 52 weeks.

Governor Glenn Youngkin spoke with 8News about AstraZeneca’s recent announcement to build their world’s-largest manufacturing ...

The deal, which Youngkin signed on Monday, has not been reviewed by the Democrat-controlled General Assembly. The governor ...

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...